IQVIA Announces Pricing of Secondary Public Offering
March 06 2019 - 6:00AM
Business Wire
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the
pricing of an underwritten, secondary public offering of 5,000,000
shares of its common stock by certain of its existing stockholders,
including affiliates of TPG Global, LLC and investment funds
associated with Bain Capital Investors, LLC (the “Selling
Stockholders”), at a price to the public of $141.00 per share.
IQVIA intends to repurchase from the underwriters 1,000,000 shares
(the “Repurchase”).
IQVIA is not offering any stock in this transaction and will not
receive any proceeds from the sale of the shares by the Selling
Stockholders in the offering. IQVIA’s per-share purchase price for
the repurchased shares will be the same as the per-share purchase
price payable by the underwriter to the Selling Stockholders. IQVIA
expects to fund the Repurchase with cash on hand and borrowings
from its revolving credit facility. The Repurchase is subject to
completion of the offering and the satisfaction of other customary
conditions.
Goldman Sachs & Co. LLC and Barclays are acting as joint
underwriters of the offering.
The offering, including the Repurchase, is expected to close on
March 8, 2019, subject to customary closing conditions.
An automatic shelf registration statement (including a
prospectus) relating to the offering of common stock was filed with
the Securities and Exchange Commission (“SEC”) on May 24, 2017 and
became effective upon filing. Before you invest, you should read
the registration statement, the prospectus, the accompanying
prospectus supplement and other documents IQVIA has made available
with the SEC for information about IQVIA and the offering. You may
obtain these documents free of charge by visiting EDGAR on the SEC
website at www.sec.gov. Alternatively, copies of the prospectus and
the accompanying prospectus supplement may be obtained from:
Goldman Sachs & Co. LLC, Prospectus Department, 200 West
Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile:
212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com; or from
Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717; by email:
barclaysprospectus@broadridge.com; or by telephone:
1-888-603-5847.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of
any such state or other jurisdiction.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation, and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190306005217/en/
IQVIA Holdings Inc.Investor Relations:Andrew Markwick,
973-257-7144andrew.markwick@iqvia.comorMedia Relations:Tor
Constantino, 484-567-6732tor.constantino@iqvia.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2024 to Oct 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Oct 2023 to Oct 2024